Abstract：Objective To investigate the level of serum lipoprotein associated phospholipase A2 (Lp-PLA2) activity in adult health examinees from a hospital in Hunan province, and to explore the influence of factors such as age, gender and lifestyle. Methods Four hundred and eight health examinees were randomly selected, and continuous monitoring assay was used to detect the level of serum Lp-PLA2 activity. All the data were statistically analyzed using SPSS 22.0 software. Results The correlation coefficients (95%CI) of Lp-PLA2 with triglyceride, cholesterol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, and apolipoprotein A1 in blood lipid indexes were 0.233 (0.496-0.628), 0.483 (0.405-0.554), 0.483 (0.404-0.554), -0.194 (-0.285-0.099), and 0.566 (0.496-0.628), respectively. Regression analysis showed a correlation of Lp-PLA2 activity with gender (β=0.227, P<0.001) and age (β=0.247, P<0.001). The level of serum Lp-PLA2 activity washigher in the male group than in the female group ((487.0±147.0)U/L vs. (422.0±128.0)U/L), with a statistically significant difference (t=4.707, P<0.001). The level of serum Lp-PLA2 activity showed statistically significant differences among different age groups (F=6.813, P<0.001), and there was an increasing trend with age. No statistically significant difference was found in the level of Lp-PLA2 activity among men from different age groups (F=1.693, P=0.152), but statistically significant differences were found in the level of Lp-PLA2 activity among women from different age groups (F=9.164, P<0.001). Further analysis showed that the level of Lp-PLA2 activity was higher in women over 40 years of age than in women under 40 years of age, showing a statistically significant difference (t=-6.339, P<0.001). Conclusions This study shows that the level of Lp-PLA2 activity is independently related to gender and age, but has no correlation with drinking, smoking, body mass index and blood pressure status. It is most closely related to ApoB in blood lipid indicators.
[1] Silva IT, Mello AP, Damasceno NR. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2): a review[J]. Lipids Health Dis, 2011,10:170. [2] MacPhee CH, Moores KE, Boyd HK, et al. Lipoprotein-associated phospholipase A2, platelet activating factor acetylhydrolase, generates two bioactive products during the oxidation of low density lipoprotein:use of a novel inhibitor[J]. Biochem J, 1999, 338(Pt 2): 479-487. [3] 叶芸,李苏亮,宋春霞,等. 缺血性脑卒中患者血浆脂蛋白相关磷脂酶A2水平及意义[J]. 临床检验杂志,2013,31(6):477-478. [4] 时永辉,牛冬梅,吴嘉,等. 冠心病患者血清脂蛋白相关磷脂酶A2与氧化低密度脂蛋白水平[J]. 临床检验杂志,2013,31(2):92-95. [5] Thompson A,Gao P, Orfei L,et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease,stroke,and mortality: collaborative analysis of 32 prospective studies[J]. Lancet, 2010, 375(9725):1536-1544. [6] Li Y. Analysis of intima-media thickness of carotid artery and lipoprotein-associated phospholipase A2 in coronary heart diseases of different types[J]. Technol Health Care, 2015,23(Suppl 1):S147-S150. [7] Garg PK, Jorgensen NW, Mcclelland RL, et al. Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: the multi-ethnic study of atherosclerosis[J]. Vasc Med, 2017, 22(1):5-12. [8] Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention[J]. Am J Cardiol, 2008, 101(12A):23F-33F. [9] Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines[J]. Am J Cardiol, 2008, 101(12A): 51F-57F. [10] 中国老年学学会心脑血管病专业委员会,中国医师协会检验医师分会心脑血管病专家委员会. 脂蛋白相关磷脂酶A2临床应用专家建议[J]. 中华心血管病杂志, 2015, 43(10): 843-847. [11] Garg PK, McClelland RL, Jenny NS, et al. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: the multi ethnic study of atherosclerosis[J]. Atherosclerosis, 2015,241(1):176-182. [12] Ridker PM, MacFadyen JG, Wolfert RL, et al. Relationship of lipoprotein associated phospholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial [J]. Clin Chem, 2012,58(5):877-886. [13] Cushman M, Judd S, Kissela B, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and coronary heart disease risk in a biracial cohort: the reasons for geographic and racial differences in stroke (regards) cohort[J]. Atherosclerosis, 2015,241(1):E9. [14] De Stefano A, Mannucci L, Massoud R, et al. Performance characteristics of lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyser and preliminary study of a healthy Italian population [J]. Biochem Med, 2017, 27(3):030701. [15] 中国高血压防治指南修订委员会,高血压联盟(中国,中华医学会心血管病学分会中国医师协会高血压专业委员会,中国医疗保健国际交流促进会高血压分会,中国老年医学学会高血压分会.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56. [16] Brilakis ES, Khera A, McGuire DK, et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels:observations from the dallas heart study [J]. Atherosclerosis, 2008,199(1):110-115. [17] Feng LM, Feng GF, Chen Y. Evaluation of lipoprotein-associated phospholipase A2 in healthy Chinese Han adultserum[J]. Lipids Health Dis, 2014, 13(1):6. [18] Huang Y, Wu Y, Yang Y, et al. Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China[J]. Sci Rep, 2017,7(1):16092. [19] Kispert SE, Marentette JO, McHowat J.Enhanced breast cancer cell adherence to the lung endothelium via PAF acetylhydrolase inhibition: a potential mechanism for enhanced metastasis in smokers [J]. Am J Physiol Cell Physiol, 2014, 307(10):C951-C956. [20] Gregson J, Stirnadel-Farrant HA, Doobaree IU,et al. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature[J]. Atherosclerosis, 2012,225(1):11-21.
2020, Vol. 27 
